UK’s Cell and Gene Therapy Catapult Partners with Japan

The Cell and Gene Therapy Catapult, one of UK’s centers of excellence, has partnered with Japan’s Forum for Innovative Regenerative Medicine to boost their respective stances in the global cell and gene therapy landscape.
Oct 03, 2017
By BioPharm International Editors

The Cell and Gene Therapy Catapult (CGT Catapult), a UK center of excellence for building up the cell and gene therapy sector in the UK, announced on Oct. 3, 2017 that it has signed a Memorandum of Understanding (MoU) with Japan’s Forum for Innovative Regenerative Medicine (FIRM) to explore the possibility of a cooperative relationship that will raise the international reach of the respective organizations.

Through this collaboration, FIRM and the CGT Catapult will share information regarding regenerative medicine technologies, policies, and legal issues by connecting major industry players in Japan and the UK. The organizations aim to increase the profile and standing of their countries in the global cell and gene therapy space through combined efforts that are outlined within the MoU.

FIRM, an incorporated association focused on accelerating research and commercialization of regenerative medicine, works closely with the Japanese government and academia to establish a social structure to safely and continuously deliver regenerative medicinal products. FIRM comprises more than 230 Japanese, including organizations from various fields such as pharmaceuticals, biotechnology, manufacturing, transportation, and insurance. These organizations offer their respective experience to the research, development, and delivery of regenerative medicine. FIRM promotes the applied use of technological developments through policy, commercialization, and network support.

Source: Cell and Gene Therapy Catapult

native1_300x100
lorem ipsum